Viral Hepatitis

You have full text access to this OnlineOpen article

A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis†

  1. Peter W. Angus1,‡,§,*,
  2. Scott J. Patterson1,
  3. Simone I. Strasser2,‡,
  4. Geoffrey W. McCaughan3,‡,
  5. Edward Gane4

Article first published online: 21 JUL 2008

DOI: 10.1002/hep.22524

Issue

Hepatology

Hepatology

Volume 48, Issue 5, pages 1460–1466, November 2008

Additional Information

How to Cite

Angus, P. W., Patterson, S. J., Strasser, S. I., McCaughan, G. W. and Gane, E. (2008), A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis. Hepatology, 48: 1460–1466. doi: 10.1002/hep.22524

Author Information

  1. 1

    Victorian Liver Transplant Unit, Austin Health, Victoria, Australia

  2. 2

    AW Morrow Gastroenterology and Liver Center, Royal Prince Alfred Hospital, New South Wales, Australia

  3. 3

    AW Morrow Gastroenterology and Liver Center, Centenary Research Institute, Australian Liver Transplant Unit, Royal Prince Alfred Hospital, University of Sydney, New South Wales, Australia

  4. 4

    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand

  1. ‡

    Peter Angus, Geoffrey McCaughan, and Simone Strasser received minor honoraria from Gilead Sciences for participation in Advisory Boards or Speakers' Bureau.

  2. §

    fax: (61)-3-94963487

*Liver Transplant Unit, Austin Health, Studley Road, Heidelberg, VIC 3084, Australia

  1. †

    Potential conflict of interest: Dr. Angus advises and received grants from Gilead. Dr. Strasser advises and is on the speakers' bureau of Gilead. Dr. McCaughan advises Gilead.

Publication History

  1. Issue published online: 28 OCT 2008
  2. Article first published online: 21 JUL 2008
  3. Accepted manuscript online: 21 JUL 2008 12:00AM EST
  4. Manuscript Accepted: 6 JUL 2008
  5. Manuscript Received: 22 APR 2008

Funded by

  • Gilead Sciences donated drug and provided unrestricted research support for this study

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (133K)

References

  • 1
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. HEPATOLOGY 1991; 13: 619–626.
  • 2
    Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. HEPATOLOGY 1991; 13: 150–157.
    Direct Link:
  • 3
    O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104–111.
  • 4
    Harrison RF, Davies MH, Goldin RD, Hubscher SG. Recurrent hepatitis B in liver allografts: a distinctive form of rapidly developing cirrhosis. Histopathology 1993; 23: 21–28.
    Direct Link:
  • 5
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842–1847.
  • 6
    McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358–1364.
  • 7
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212–1215.
  • 8
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. HEPATOLOGY 1998; 28: 585–589.
    Direct Link:
  • 9
    Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 434–439.
    Direct Link:
  • 10
    Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888–894.
  • 11
    Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650–654.
  • 12
    Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374–381.
    Direct Link:
  • 13
    Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. HEPATOLOGY 2000; 31: 496–501.
    Direct Link:
  • 14
    Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. HEPATOLOGY 2002; 35: 176–181.
    Direct Link:
  • 15
    Albeniz Arbizu E, Barcena Marugan R, Oton Nieto E, Carrera Alonso E, Garcia Gonzalez M, Moreno Garcia J, et al. Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: preliminary results. Transplant Proc 2003; 35: 1848–1849.
  • 16
    Bienzle U, Gunther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. HEPATOLOGY 2003; 38: 811–819.
  • 17
    Lo CM, Liu CL, Chan SC, Lau GK, Fan ST. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43: 283–287.
  • 18
    Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007; 13: 367–373.
    Direct Link:
  • 19
    McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512–519.
    Direct Link:
  • 20
    Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429–433.
    Direct Link:
  • 21
    Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931–937.
  • 22
    Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445–1451.
  • 23
    van der Poorten D, Prakoso E, Khoo TL, Ngu MC, McCaughan GW, Strasser SI, et al. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol 2007; 22: 1500–1505.
    Direct Link:
  • 24
    Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90.
  • 25
    Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349–360.
    Direct Link:
  • 26
    Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M. Five year follow-up of a randomized study comparing lamivudine vs. lamivudine+HBIG in the prevention of HBV recurrence after liver transplantation [Abstract]. HEPATOLOGY 2005; 42(Suppl): 491A.
  • 27
    Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. HEPATOLOGY 2004; 38: 86–95.
    Direct Link:
  • 28
    Dan Y, Wai C, Yeoh K, Lim S. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost effectiveness analysis. Liver Transpl 2006; 12: 736–746.
    Direct Link:
  • 29
    Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20: 206–210.
    Direct Link:
  • 30
    Gane EJ, Strasser SI, Patterson SJ, McCaughan GW, Angus PW. A prospective study on the safety and efficacy of lamivudine and adefovir prophylaxis in HBsAg positive liver transplantation candidates [Abstract]. HEPATOLOGY 2007; 46(Suppl): 479A.
View Full Article with Supporting Information (HTML) Get PDF (133K)